ICCC Stock Analysis

ImmuCell Corporation
HEALTHCARE BIOTECHNOLOGY

Back to Winners View Yahoo Finance Chart
Buy on the Dip
Strong Caution Mixed Weak Unavailable
StockValueFinder Grade
D
48.01 / 100
Below Average
Confidence: High (89.0%) Coverage: 89.0%
Business Quality 30.8
Financial Strength 46.3
Earnings & Growth 62.1
Valuation 27.9
Market Strength 87.2
The grade combines Business Quality, Financial Strength, Earnings & Growth, Valuation, and Market Strength. Rating and Trend remain separate signals.
Rating AVOID
Avoid
The screening rules are warning against this setup.
Rating is the simple decision label from the screening rules.
Trend STRONG BUY TREND
Bullish
The available trend signal is constructive.
Trend shows whether price action is helping or hurting the setup.
P/E Ratio 146.43
High Expectations
Very high P/E requires strong future results to justify the price.
P/E shows how much investors pay for each dollar of earnings.
ROIC -2.58%
Poor
Negative ROIC suggests capital is not being used profitably.
ROIC measures how efficiently capital turns into profit.
Debt Payback 6.11 yrs
Weak
A long payback period can raise financial-risk concerns.
Debt payback estimates how quickly debt could be covered.
Interest Coverage 3.76x
Caution
Coverage is acceptable but leaves less cushion.
Interest coverage shows how easily earnings cover interest costs.
Price $10.25
Market Price
Price alone is not a buy or sell signal.
Price should be judged with valuation, quality, and trend.
Last updated: 2026-10-26 01:04:47

Performance Overview

Trailing adjusted-close returns as of 2026-07-10. Benchmark is SPY.

YTD Return

ICCC +77.07%
SPY +11.30%

1-Year Return

ICCC +67.02%
SPY +21.97%

3-Year Return

ICCC +120.00%
SPY +78.24%

5-Year Return

ICCC +9.83%
SPY +85.50%

Returns are calculated from adjusted close prices and may differ from broker or research-site totals depending on data source, dividend handling, benchmark choice, and latest available trading date.

Legacy Screening Checks

This page uses cached SQL data from the latest StockValueFinder scan, so it loads fast without hitting Alpha Vantage on every page view.

17%
EPS Strength
FAIL

Looks for positive and improving earnings per share.

ROIC 10%+
FAIL

Looks for strong return on invested capital.

Interest Coverage 6+
FAIL

Checks whether operating income comfortably covers interest expense.

Debt Payback ≤ 3 Years
FAIL

Checks whether free cash flow could pay down long-term debt quickly.

P/E 15 or Less
FAIL

Checks whether valuation is reasonable under the current rule set.

Moving Average Trend
STRONG BUY TREND

Uses 20-day, 50-day, and 200-day moving averages for entry timing context.

A high StockValueFinder score is a research signal, not a guarantee. Strong companies can still fall during recessions, sector downturns, valuation resets, or company-specific events. Always review the business, risks, SEC filings, valuation, and your personal investment goals before buying.

Cached Technical Data

Moving average values from the latest stored scan.

20-Day MA10.13
50-Day MA10.00
200-Day MA8.77
MA Score5

Latest Published Stock Research

Research generated: October 24, 2026

ICCC Stock Analysis: Why ImmuCell Corporation Scored 17% in Stock Value Finder

ImmuCell Corporation (ICCC): A Comprehensive StockValueFinder Review

ImmuCell Corporation is a biotechnology company specializing in developing innovative solutions for animal health. This article provides an educational review of the stock's performance according to the StockValueFinder metrics, focusing on key financial indicators and overall investment considerations.

Why the StockValueFinder Score Matters StockValueFinder evaluates stocks based on multiple financial metrics designed to identify companies with strong fundamentals. The score ranges from 0% to 100%, where a higher percentage indicates better adherence to the criteria set by the system, which is typically associated with healthier financial performance and potentially lower risk.

ImmuCell Corporation (ICCC) has received a StockValueFinder score of 17%, translating into an "AVOID" rating. This low score suggests that ImmuCell does not meet many of the fundamental metrics that StockValueFinder deems important for long-term investment success, indicating potential risks or weaknesses in its financial health.

EPS Strength and Consistency Earnings Per Share (EPS) is a critical measure of profitability per outstanding share. A consistent positive EPS over time indicates stable earnings, which is favorable for investors seeking reliable returns.

**StockValueFinder Result:** Did not pass

Given that detailed historical EPS data was not provided in the supplied facts, we can only refer to the system's evaluation. However, generally speaking, a company with fluctuating or negative EPS values would likely fail this test, as it suggests inconsistent earnings and potential financial instability.

For example

A company with an EPS of $2 per share for several consecutive quarters might pass this test. - Conversely, a company showing erratic EPS figures such as -$0.50, $1.00, -$0.75, and $0.80 over the same period would likely fail.

ROIC and Capital Efficiency Return on Invested Capital (ROIC) measures how effectively a company uses its capital to generate returns. A higher ROIC indicates better use of resources and stronger profitability relative to invested assets.

**StockValueFinder Result:** Did not pass

**Actual Value:** -2.58% - **Preferred Range:** 10% or higher - **Example:** A company with a 15% ROIC is generally using its capital more efficiently than one with a 4% ROIC, indicating better financial health and potential for growth.

Interest Coverage Ratio The interest coverage ratio measures a company's ability to pay the interest on outstanding debt. It is calculated by dividing earnings before interest and taxes (EBIT) by total interest expenses.

**StockValueFinder Result:** Did not pass

**Preferred Range:** 6 or higher - **Example:** A company with an interest coverage of 8x can comfortably cover its interest payments, whereas a ratio of 2x suggests the company may struggle to meet these obligations during tough financial periods.

Debt Payback and Balance Sheet Discipline Debt payback years indicate how long it would take for a company's operating income to repay all outstanding debt. This metric helps assess the company’s leverage and ability to manage its debt load effectively.

**StockValueFinder Result:** Did not pass

**Actual Value:** 6.11 years - **Preferred Range:** 3 years or less - **Example:** A lower payback period, such as 2 years, is generally more attractive than a longer period of 7 years, indicating better financial discipline and reduced risk.

P/E Ratio and Valuation Discipline The Price-to-Earnings (P/E) ratio compares the stock price to earnings per share. It helps investors understand how much they are paying for each dollar of company earnings.

**StockValueFinder Result:** Did not pass

**Actual Value:** 146.43 - **Preferred Range:** 15 or lower - **Example:** A P/E ratio of 8 may be more value-oriented than a P/E ratio of 40, assuming the business quality is sound and earnings are stable.

Moving Average Trend and Entry Timing The moving average trend helps identify trends in stock price movements. It provides insights into whether the stock is currently experiencing upward or downward momentum.

**StockValueFinder Result:** - **Moving Average Signal:** STRONG BUY TREND - **Entry Signal:** N/A

While a strong buy trend suggests positive momentum, it does not guarantee future performance. The entry signal being "N/A" means there's no specific recommendation on when to enter the stock based on current trends.

Overall Financial Strengths and Weaknesses **Strengths:** - Positive moving average trend indicating recent price appreciation.

**Weaknesses:** - Low StockValueFinder score of 17% with an "AVOID" rating, highlighting significant financial weaknesses across multiple metrics. - Negative ROIC (-2.58%) suggesting poor capital efficiency and potentially weak profitability. - High P/E ratio (146.43) indicating the stock may be overvalued relative to earnings. - Debt payback years of 6.11, which is longer than preferred for managing debt effectively.

Risks and Limitations Investing in ImmuCell Corporation involves several risks due to its poor performance on key financial metrics: - **Financial Instability:** Negative ROIC and high P/E ratio suggest potential earnings instability. - **Debt Management:** Longer payback period indicates higher leverage risk. - **Valuation Concerns:** Overvalued stock price relative to earnings may lead to reduced returns or losses if the valuation corrects.

Educational Conclusion This article serves as a comprehensive guide for understanding ImmuCell Corporation's financial health based on StockValueFinder metrics. The low score and multiple failed tests highlight significant risks associated with investing in ICCC, emphasizing the importance of thorough research before making investment decisions.

Investors should carefully consider these factors alongside their own risk tolerance and investment goals when evaluating potential investments.

**Disclaimer:** This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings

Research Attribution
Max Qwen II

Specializing in monetary economics, market incentives, and investment risk.

AI-assisted research generated October 24, 2026

30-Day Trendline Analysis

Optional intraday chart with rising support, falling resistance, and multi-timeframe views.

Load detailed price structure only when needed. Downloads roughly 30 days of 5-minute candles, identifies swing points, then calculates validated support and resistance lines.
Scroll to Top